Causal Relationship Between Circulating Insulin-like Growth Factor-1 and Parkinson's Disease: a Two-sample Mendelian Randomization Study

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 May 3

PMID 38699559

Authors

Jiahao Xu

Peidong Fan

Jiacheng Yang

Mingjuan Yin

Jun Wu

Chao Chen

Jindong Ni

Affiliations

Soon will be listed here.

Abstract

Background: Linear associations between circulating insulin-like growth factor-1 (IGF-1) levels and Parkinson's disease (PD) have been evidenced in observational studies. Yet, the causal relationship between IGF-1 levels and PD remains obscure. We conducted Mendelian randomization to examine the correlation between genetically predicted IGF-1 levels and PD.

Methods: By reviewing genome-wide association studies (GWAS) that are publicly accessible, we uncovered SNPs linked to both serum concentrations of IGF-1 and PD. A two-sample Mendelian randomization (MR) analysis was carried out to evaluate the individual effect of IGF-1 on PD.

Results: In a primary causal effects model in MR analysis, employing the inverse-variance weighted (IVW) method, IGF-1 levels exhibited a notable association with the risk of PD (OR, 1.020, 95% CI, 1.003-1.038, = 0.0215). Multiple evaluations revealed that horizontal pleiotropy was improbable to distort the main results (MR-Egger: P PD intercept =0.719), and no bias was detected by leave-one-out analysis.

Conclusion: This study unearthed evidence indicating that heightened IGF-1 levels might be causally correlated with an increased risk of PD.

References

Burgess S, Thompson S . Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32(5):377-389. PMC: 5506233. DOI: 10.1007/s10654-017-0255-x. View

Davey Smith G, Ebrahim S . 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32(1):1-22. DOI: 10.1093/ije/dyg070. View

Mosiolek A, Mosiolek J, Jakima S, Pieta A, Szulc A . Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD). J Clin Med. 2021; 10(15). PMC: 8346988. DOI: 10.3390/jcm10153377. View

Davey Smith G, Hemani G . Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014; 23(R1):R89-98. PMC: 4170722. DOI: 10.1093/hmg/ddu328. View

Burgess S, Dudbridge F, Thompson S . Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2015; 35(11):1880-906. PMC: 4832315. DOI: 10.1002/sim.6835. View

Davies N, Hill W, Anderson E, Sanderson E, Deary I, Davey Smith G . Multivariable two-sample Mendelian randomization estimates of the effects of intelligence and education on health. Elife. 2019; 8. PMC: 6748790. DOI: 10.7554/eLife.43990. View

Milligan B . Maximum-likelihood estimation of relatedness. Genetics. 2003; 163(3):1153-67. PMC: 1462494. DOI: 10.1093/genetics/163.3.1153. View

Heemels M . Neurodegenerative diseases. Nature. 2016; 539(7628):179. DOI: 10.1038/539179a. View

Scorza F, Fiorini A, Scorza C, Finsterer J . Cardiac abnormalities in Parkinson's disease and Parkinsonism. J Clin Neurosci. 2018; 53:1-5. DOI: 10.1016/j.jocn.2018.04.031. View

10.

Castilla-Cortazar I, Aguirre G, Femat-Roldan G, Martin-Estal I, Espinosa L . Is insulin-like growth factor-1 involved in Parkinson's disease development?. J Transl Med. 2020; 18(1):70. PMC: 7014772. DOI: 10.1186/s12967-020-02223-0. View

11.

Pringsheim T, Jette N, Frolkis A, Steeves T . The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13):1583-90. DOI: 10.1002/mds.25945. View

12.

Allwright M, Mundell H, Sutherland G, Austin P, Guennewig B . Machine learning analysis of the UK Biobank reveals IGF-1 and inflammatory biomarkers predict Parkinson's disease risk. PLoS One. 2023; 18(5):e0285416. PMC: 10168570. DOI: 10.1371/journal.pone.0285416. View

13.

Burgess S, Bowden J, Fall T, Ingelsson E, Thompson S . Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2016; 28(1):30-42. PMC: 5133381. DOI: 10.1097/EDE.0000000000000559. View

14.

Ong J, Macgregor S . Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner's perspective. Genet Epidemiol. 2019; 43(6):609-616. PMC: 6767464. DOI: 10.1002/gepi.22207. View

15.

Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi K, Sipido E . The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020; 5(10):e551-e567. DOI: 10.1016/S2468-2667(20)30190-0. View

16.

Fernandez A, Jimenez S, Mecha M, Davila D, Guaza C, Vitorica J . Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. Mol Psychiatry. 2011; 17(7):705-18. DOI: 10.1038/mp.2011.128. View

17.

Berson A, Nativio R, Berger S, Bonini N . Epigenetic Regulation in Neurodegenerative Diseases. Trends Neurosci. 2018; 41(9):587-598. PMC: 6174532. DOI: 10.1016/j.tins.2018.05.005. View

18.

Ghazi Sherbaf F, Mohajer B, Ashraf-Ganjouei A, Mojtahed Zadeh M, Javinani A, Moghaddam H . Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure. Front Endocrinol (Lausanne). 2018; 9:608. PMC: 6224341. DOI: 10.3389/fendo.2018.00608. View

19.

Bowden J, Davey Smith G, Burgess S . Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44(2):512-25. PMC: 4469799. DOI: 10.1093/ije/dyv080. View

20.

Dorsey E, Constantinescu R, Thompson J, Biglan K, Holloway R, Kieburtz K . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2006; 68(5):384-6. DOI: 10.1212/01.wnl.0000247740.47667.03. View